Document Type

Article

Publication Date

1-8-2020

Abstract

© 2019 Endocrine Society 2019. Context: Oncostatin M (OSM) plays a key role in inflammation, but its regulation and function during obesity is not fully understood. Objective: The aim of this study was to evaluate the relationship of OSM with the inflammatory state that leads to impaired glucose homeostasis in obesity. We also assessed whether OSM immunoneutralization could revert metabolic disturbances caused by a high-fat diet (HFD) in mice. Design: 28 patients with severe obesity were included and stratified into two groups: (1) glucose levels /dL and (2) glucose levels >100 mg/dL. White adipose tissue was obtained to examine OSM gene expression. Human adipocytes were used to evaluate the effect of OSM in the inflammatory response, and HFD-fed C57BL/6J mice were injected with anti-OSM antibody to evaluate its effects. Results: OSM expression was elevated in subcutaneous and visceral fat from patients with obesity and hyperglycemia, and correlated with Glut4 mRNA levels, serum insulin, homeostatic model assessment of insulin resistance, and inflammatory markers. OSM inhibited adipogenesis and induced inflammation in human adipocytes. Finally, OSM receptor knockout mice had increased Glut4 mRNA levels in adipose tissue, and OSM immunoneutralization resulted in a reduction of glucose levels and Ccl2 expression in adipose tissue from HFD-fed mice. Conclusions: OSM contributes to the inflammatory state during obesity and may be involved in the development of insulin resistance.

Publication Source (Journal or Book title)

Journal of Clinical Endocrinology and Metabolism

Download
COinS